One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
UFlex has committed close to US $ 10 million towards various initiatives at its overseas and Indian plants to repurpose plastic waste
The startup’s AI platform uses AI algorithms to automatically detect abnormalities and diseases in medical images, reducing patient misdiagnosis and increasing radiologists’ productivity
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
_256_384.jpg)
In the period April to August 2021, exports stood at Rs 73,469.29 crores compared to Rs 72,275.22 crores for the period April to August 2020 a growth of 1.65 per cent
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
